Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis

© The Author(s) 2020. Published by Oxford University Press..

Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but some patients suffer from immune-related adverse events during or after ICI treatments. The monoclonal antibody infliximab is usually chosen as a salvage treatment to combat corticosteroid-resistant adverse events, but infliximab is not recommended as a response to hepatitis because of the potential risk of liver failure. An alternative treatment option has not been established. We treated a head and neck cancer patient (a 50-year-old Japanese male) who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:2020

Enthalten in:

Oxford medical case reports - 2020(2020), 4 vom: 31. Apr., Seite omaa027

Sprache:

Englisch

Beteiligte Personen:

Nakano, Kenji [VerfasserIn]
Nishizawa, Masatoshi [VerfasserIn]
Fukuda, Naoki [VerfasserIn]
Urasaki, Tetsuya [VerfasserIn]
Wang, Xiaofei [VerfasserIn]
Mitani, Hiroki [VerfasserIn]
Takahashi, Shunji [VerfasserIn]

Links:

Volltext

Themen:

Head and neck cancer
Immune-related adverse event
Journal Article
Mycophenolate
Nivolumab

Anmerkungen:

Date Revised 28.09.2020

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.1093/omcr/omaa027

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM310580080